Lugano, Switzerland, 7 May 2025 – ESMO Breast Cancer 2025 will take place between 14-17 May in Munich, Germany, bringing together international experts to present and discuss the latest advances in breast cancer research and care. The congress will cover a broad spectrum of topics, from translational research and developments in molecular and functional diagnostics to emerging therapies. Among the key themes are the clinical application of circulating tumour DNA (ctDNA), the evolving role of immunotherapies and antibody-drug conjugates (ADCs), new approaches for managing breast cancer in younger patients.
The event will be accessible both in person and online, with sessions available via live stream on the Virtual Congress Platform.
Programme picks
-
Long-term data on survival benefits and safety in patients with early HER2-positive operable breast cancer at high risk of relapse, 11.3 years after receiving standard-of-care combination therapy.
-
Novel findings from large trials on predictive biomarkers for foregoing chemotherapy in early breast cancer treated with endocrine-based therapy.
-
Novel data on the value of ctDNA as a prognostic and dynamic biomarker in various breast cancer settings and its utility in practice to guide decision-making on therapies.
-
New evidence on the role of tumour-infiltrating lymphocytes (TILs) in the prognostication of early-stage triple negative breast cancer, within a broader effort to 'right-size' adjuvant therapy based on patients’ individual risk profiles.
-
Promising emerging targets for antibody-drug conjugates (ADCs) across different breast cancer settings, along with insights into resistance mechanisms and future directions in the field.
-
New data on disease outcome, pregnancy and fetal outcomes after breast cancer.
-
“Development of targeted therapies for HR+ breast cancer”, Award Lecture by Gabriel N. Hortobagyi, recipient of the 2025 ESMO Breast Cancer Award, 14 May, 13:00-13:40 CEST.
-
“Who benefits from immunotherapy for breast cancer?”, Keynote lecture by Sherene Loi, 14 May, 15:35-16:00 CEST.
- “A decade of Breast Cancer in Young Women: What we have done and where we are going” Keynote Lecture by Ann H. Partridge, 16 May,16:45- 17:15 CEST.
The abstracts will be published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ESMO Breast Cancer 2025. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditation will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
ESMO Press Office
press@esmo.org